JP Morgan Chase
LAB icon

JP Morgan Chase’s Standard BioTools LAB Stock Holding History

JP Morgan Chase’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$109K Sell
117,886
-8,800
-7% -$10.7K ﹤0.01% 5782
2025
Q4 		$162K Buy
126,686
+1,336
+1% +$1.79K ﹤0.01% 5633
2025
Q3 		$163K Sell
125,350
-18,821
-13% -$24.7K ﹤0.01% 5626
2025
Q2 		$173K Sell
144,171
-1,756
-1% -$1.95K ﹤0.01% 5306
2025
Q1 		$158K Buy
145,927
+5,468
+4% +$7.68K ﹤0.01% 5352
2024
Q4 		$246K Buy
140,459
+711
+0.5% +$1.32K ﹤0.01% 5384
2024
Q3 		$270K Buy
139,748
+9,995
+8% +$19.6K ﹤0.01% 5265
2024
Q2 		$230K Sell
129,753
-462,893
-78% -$1.13M ﹤0.01% 5097
2024
Q1 		$1.61M Buy
592,646
+448,270
+310% +$1.08M ﹤0.01% 4018
2023
Q4 		$319K Buy
144,376
+143,065
+10,913% +$305K ﹤0.01% 5066
2023
Q3 		$3.8K Hold
1,311
– – ﹤0.01% 6420
2023
Q2 		$2.53K Hold
1,311
– – ﹤0.01% 6300
2023
Q1 		$2K Hold
1,311
– – ﹤0.01% 6424
2022
Q4 		$1K Hold
1,311
– – ﹤0.01% 6416
2022
Q3 		$1K Hold
1,311
– – ﹤0.01% 6338
2022
Q2 		$2K Sell
1,311
-34,948
-96% -$86.5K ﹤0.01% 6287
2022
Q1 		$130K Sell
36,259
-111,577
-75% -$385K ﹤0.01% 5396
2021
Q4 		$579K Sell
147,836
-10,543
-7% -$49.4K ﹤0.01% 4730
2021
Q3 		$1.04M Sell
158,379
-35,334
-18% -$232K ﹤0.01% 4278
2021
Q2 		$1.19M Sell
193,713
-453,095
-70% -$2.42M ﹤0.01% 4179
2021
Q1 		$2.92M Sell
646,808
-565,903
-47% -$3.11M ﹤0.01% 3418
2020
Q4 		$7.28M Buy
1,212,711
+35,329
+3% +$232K ﹤0.01% 2472
2020
Q3 		$9.04M Sell
1,177,382
-98,576
-8% -$681K ﹤0.01% 2114
2020
Q2 		$5.12M Buy
1,275,958
+254,868
+25% +$888K ﹤0.01% 2436
2020
Q1 		$2.59M Buy
1,021,090
+992,781
+3,507% +$3.26M ﹤0.01% 2770
2019
Q4 		$99K Buy
28,309
+3,965
+16% +$13.9K ﹤0.01% 4902
2019
Q3 		$113K Sell
24,344
-72,685
-75% -$573K ﹤0.01% 4855
2019
Q2 		$1.18M Sell
97,029
-28,775
-23% -$367K ﹤0.01% 3752
2019
Q1 		$1.67M Sell
125,804
-141,287
-53% -$1.49M ﹤0.01% 3457
2018
Q4 		$2.3M Buy
267,091
+194,752
+269% +$1.52M ﹤0.01% 3178
2018
Q3 		$542K Buy
72,339
+63,721
+739% +$453K ﹤0.01% 4240
2018
Q2 		$51K Sell
8,618
-23
-0.3% -$131 ﹤0.01% 5076
2018
Q1 		$51K Sell
8,641
-58,744
-87% -$386K ﹤0.01% 4806
2017
Q4 		$396K Buy
67,385
+1,099
+2% +$6.02K ﹤0.01% 4166
2017
Q3 		$345K Buy
66,286
+65,846
+14,965% +$277K ﹤0.01% 3947
2017
Q2 		$2K Sell
440
-18,445
-98% -$87.5K ﹤0.01% 4851
2017
Q1 		$107K Buy
18,885
+18,550
+5,537% +$118K ﹤0.01% 4306
2016
Q4 		$2K Buy
+335
New +$2.1K ﹤0.01% 4939
2016
Q3 		– Sell
-3,392
Closed -$31K – 4681
2016
Q2 		$31K Buy
3,392
+1,410
+71% +$13.3K ﹤0.01% 4145
2016
Q1 		$17K Buy
+1,982
New +$14.3K ﹤0.01% 4123
2015
Q4 		– Sell
-1,993,082
Closed -$16.2M – 4746
2015
Q3 		$16.2M Sell
1,993,082
-942,728
-32% -$14.8M ﹤0.01% 1411
2015
Q2 		$71M Buy
2,935,810
+256,252
+10% +$8.09M 0.02% 738
2015
Q1 		$113M Sell
2,679,558
-252,056
-9% -$9.96M 0.03% 590
2014
Q4 		$98.9M Buy
2,931,614
+411,720
+16% +$11.7M 0.02% 643
2014
Q3 		$61.7M Buy
2,519,894
+13,175
+0.5% +$370K 0.01% 805
2014
Q2 		$73.7M Buy
2,506,719
+1,199,582
+92% +$38.4M 0.02% 673
2014
Q1 		$57.6M Sell
1,307,137
-147,026
-10% -$6.47M 0.02% 741
2013
Q4 		$55.7M Sell
1,454,163
-215,970
-13% -$6.36M 0.02% 752
2013
Q3 		$36.6M Buy
1,670,133
+162,060
+11% +$3.18M 0.01% 970
2013
Q2 		$26.3M Buy
+1,508,073
New +$26.5M 0.01% 1082

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

JP Morgan Chase's LAB Position: Q1 2026 in Review

JP Morgan Chase reduced its Standard BioTools (LAB) stake by 6.9% in Q1 2026, selling an estimated $10.7K and leaving 117,886 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #5782.

JP Morgan Chase first reported a position in LAB in Q2 2013 and has held it in 50 quarters since. The position peaked at $113M in Q1 2015. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • JP Morgan Chase held 117,886 shares of Standard BioTools worth $109K as of Q1 2026.
  • JP Morgan Chase sold 8,800 Standard BioTools shares in Q1 2026, an estimated $10.7K.
  • Standard BioTools made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5782 holding.
  • JP Morgan Chase first reported a position in Standard BioTools in Q2 2013 and has held it in 50 quarters since.
  • JP Morgan Chase's Standard BioTools position peaked at $113M in Q1 2015.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.